We discuss the diagnosis and management of central serous chorioretinopathy with photodynamic therapy with Dr. Andrew Lotery, Professor of Ophthalmology, University of Southhampton, United Kingdom.

In this episode, we discuss the use of low dose cryogenic application for anesthesia prior to intravitreal injection with Dr. Michael Singer, Adjunct Professor University of Texas Health Science Center, San Antonio.

In our latest update, we discuss current treatment of retinopathy of prematurity as well as new developments in disease prevention with Dr. Darius Moshfeghi, Professor of Ophthalmology, Stanford University, Director, Retina Division, Byers Eye Institute.

In this update, we review the TKI program of Eyepoint Pharmaceuticals with Dr. Jay Duker, President and CEO.

We discuss a study that showed that an artificial intelligence powered system can detect clinically significant fluid as well as experienced observers using the Notal Home OCT with Dr. Ted Leng, Professor of Ophthalmology, Byers Eye Institute, Stanford University.

We discuss studies documenting the undertreatment of diabetic macular edema and possible strategies for alleviating it with Dr. Matthew Starr, Assistant Professor, Mayo Clinic, Rochester, Minnesota.

In this episode, we discuss promising results of gene therapy, administered suprachoroidally, for the treatment of nonproliferation diabetic retinopathy without macular edema with Charles Wykoff, MD, Ph.D., Retina Consultants of Houston.

We discuss promising Phase 2 results from Nanoscope regarding the use of optogenetics for treatment of retinal degenerations with Allen Ho, MD, Professor of Ophthalmology, Wills Eye Hospital.

We discuss the early results of the use of artificial intelligence in the management of macular disorders with Dr. Pearse Keane, the world's first Professor of Artificial Medical Intelligence, University College London, Moorfields Eye Hospital.

We discuss with Dr. Rajesh C. Rao, Leonard Miller Professor of Ophthalmology, Kellogg Eye Center, University of Michigan, the results of a Phase I trial exploring the use of stem cells injected subretinally in eyes with geographic atrophy. The results are promising.